Alumis Inc. (ALMS) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 902.16M USD. 52-week range 4.28 to 31.35 USD. Data as of 2026-10-09.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal ...